Home 
Bratislava Medical Journal 2019 Bratislava Medical Journal Vol.120, No.2, p.131–138, 2019
Bratislava Medical Journal 2019 Bratislava Medical Journal Vol.120, No.2, p.131–138, 2019
Journal info
|
||||
Select Journal
Webshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Bratislava Medical Journal Vol.120, No.2, p.131–138, 2019 |
||
| Title: The role of selenium in bevacizumab induced cardiotoxicity | ||
| Author: C. R. Oncel, I. S. Ovey | ||
| Abstract: OBJECTIVE: We investigated the role of selenium in bevacizumab induced cardiotoxicity and involvement of transient receptor potential vanilloid 1 (TRPV1) channels in cardiomyocytes. MATERIALS AND METHODS: All cells (Human cardiomyocyte cell line) were cultured at 37 °C. We divided the cells into seven groups as control, bevacizumab, bevacizumab + capsazepin, bevacizumab + selenium, bevacizumab + selenium + capsazepin, selenium and selenium + capsazepin groups. Cells in the groups were stimulated with capsaicin and inhibited with capsazepin in related experiments for activation and inactivation of TRPV1 channels, respectively. RESULTS: Cytosolic calcium, apoptosis and intracellular ROS production levels were lower in bevacizumab + selenium group than in the bevacizumab group of cardiomyocytes (p ˂ 0.001). Also, values were markedly lower in the bevacizumab + selenium + capsazepine group when compared to the bevacizumab + selenium group (p ˂ 0.001). CONCLUSION: We found that cytosolic calcium, apoptosis, intracellular ROS production levels were increased in bevacizumab induced cardiotoxicity and selenium treatment could have beneficial effects on these parameters (Fig. 5, Ref. 51). |
||
| Keywords: apoptosis, bevacizumab, cardiomyocyte, transient receptor potential vanilloid 1, selenium | ||
| Published online: 17-Feb-2019 | ||
| Year: 2019, Volume: 120, Issue: 2 | Page From: 131, Page To: 138 | |
| doi:10.4149/BLL_2019_021 |
||
|
|
 download file |
|